What is the share price of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) today?
The share price of JBCHEPHARM as on 24th June 2025 is ₹1812.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?
The past returns of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share are- Past 1 week: 1.41%
- Past 1 month: 4.88%
- Past 3 months: 8.82%
- Past 6 months: -3.43%
- Past 1 year: 2.40%
- Past 3 years: 135.45%
- Past 5 years: 396.55%
What are the peers or stocks similar to J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM)?
The peers or stocks similar to J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) include:What is the dividend yield % of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?
The current dividend yield of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is 0.86.What is the market cap of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is ₹28026.62 Cr as of 24th June 2025.What is the 52 week high and low of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) share?
The 52-week high of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is ₹2030 and the 52-week low is ₹1385.75.What is the PE and PB ratio of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) stock?
The P/E (price-to-earnings) ratio of J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) is 42.49. The P/B (price-to-book) ratio is 9.59.Which sector does J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) belong to?
J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) shares?
You can directly buy J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
J B Chemicals and Pharmaceuticals Ltd
JBCHEPHARM Share Price
JBCHEPHARM Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JBCHEPHARM Performance & Key Metrics
JBCHEPHARM Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
42.49 | 9.59 | 0.86% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
35.49 | 6.52 | 0.85% |
from 13 analysts
Price Upside
Earnings Growth
Rev. Growth
JBCHEPHARM Company Profile
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs).
JBCHEPHARM Sentiment Analysis
JBCHEPHARM Sentiment Analysis
JBCHEPHARM Stock Summary · May 2025
In Q4 FY25, the company demonstrated robust operational momentum with a 10% revenue increase and a 15% rise in net profit, driven by strong domestic performance, particularly in the chronic portfolio, which outpaced industry growth. While the domestic market remains a cornerstone, contributing 60% of revenues, international expansion, especially in the CDMO segment, is poised for significant growth through new product launches and strategic partnerships. Despite facing competitive pressures in the branded generics space, the company is committed to enhancing profitability through improved margins and operational efficiencies. Ongoing investments and a diversified revenue stream position the company favorably for future growth, even as it navigates market challenges and evolving dynamics.
JBCHEPHARM Stock Growth Drivers
JBCHEPHARM Stock Growth Drivers
8Strong Financial Performance
The company reported a 10% increase in revenue to INR 949 crore for Q4 FY25,
Robust Prescription Growth
The company has achieved a prescription growth rate of 17% CAGR over the past four
JBCHEPHARM Stock Challenges
JBCHEPHARM Stock Challenges
4Decline in API Business
The API business has been experiencing a decline over the past two years, primarily due
Subdued Growth in Indian Pharmaceutical Market
The Indian pharmaceutical market has experienced subdued growth, currently at around 8%, with volume growth
JBCHEPHARM Forecast
JBCHEPHARM Forecasts
Price
Revenue
Earnings
JBCHEPHARM Share Price Forecast
JBCHEPHARM Share Price Forecast
All values in ₹
All values in ₹
JBCHEPHARM Company Revenue Forecast
JBCHEPHARM Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
JBCHEPHARM Stock EPS (Earnings Per Share) Forecast
JBCHEPHARM Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
JBCHEPHARM
JBCHEPHARM
Income
Balance Sheet
Cash Flow
JBCHEPHARM Income Statement
JBCHEPHARM Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,394.45 | 1,445.49 | 1,684.64 | 1,825.40 | 2,154.90 | 2,463.47 | 3,159.22 | 3,521.45 | 3,956.31 | 3,956.31 | ||||||||||
Raw Materials | 519.54 | 544.41 | 615.76 | 634.79 | 742.76 | 860.38 | 1,179.20 | 1,228.90 | 2,886.15 | 2,886.15 | ||||||||||
Power & Fuel Cost | 54.89 | 58.28 | 63.29 | 61.54 | 62.60 | 71.47 | 91.54 | 88.08 | ||||||||||||
Employee Cost | 217.34 | 251.10 | 288.18 | 322.92 | 340.60 | 439.24 | 543.45 | 601.41 | ||||||||||||
Selling & Administrative Expenses | 174.28 | 205.31 | 234.51 | 228.72 | 233.56 | 358.90 | 448.81 | 501.94 | ||||||||||||
Operating & Other expenses | 145.85 | 131.98 | 135.62 | 159.19 | 102.59 | 150.79 | 190.53 | 166.96 | ||||||||||||
EBITDA | 282.55 | 254.41 | 347.28 | 418.24 | 672.79 | 582.69 | 705.69 | 934.16 | 1,070.16 | 1,070.16 | ||||||||||
Depreciation/Amortization | 47.22 | 56.97 | 55.64 | 66.32 | 68.67 | 72.66 | 114.41 | 138.32 | 171.04 | 171.04 | ||||||||||
PBIT | 235.33 | 197.44 | 291.64 | 351.92 | 604.12 | 510.03 | 591.28 | 795.84 | 899.12 | 899.12 | ||||||||||
Interest & Other Items | 5.37 | 3.49 | 4.65 | 3.03 | 7.24 | 5.12 | 36.05 | 44.33 | 11.73 | 11.73 | ||||||||||
PBT | 229.96 | 193.95 | 286.99 | 348.89 | 596.88 | 504.91 | 555.23 | 751.51 | 887.39 | 887.39 | ||||||||||
Taxes & Other Items | 45.88 | 55.61 | 93.52 | 76.85 | 148.92 | 119.54 | 145.40 | 198.88 | 227.81 | 227.81 | ||||||||||
Net Income | 184.08 | 138.34 | 193.47 | 272.04 | 447.96 | 385.37 | 409.83 | 552.63 | 659.58 | 659.58 | ||||||||||
EPS | 10.85 | 8.22 | 11.81 | 17.27 | 28.98 | 24.93 | 26.50 | 35.66 | 42.45 | 42.50 | ||||||||||
DPS | 0.50 | 1.00 | 2.50 | 5.50 | 8.25 | 8.25 | 8.88 | 12.25 | 15.50 | 15.25 | ||||||||||
Payout ratio | 0.05 | 0.12 | 0.21 | 0.32 | 0.28 | 0.33 | 0.33 | 0.34 | 0.37 | 0.36 |
JBCHEPHARM Company Updates
Investor Presentation
JBCHEPHARM Stock Peers
JBCHEPHARM Past Performance & Peer Comparison
JBCHEPHARM Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
J B Chemicals and Pharmaceuticals Ltd | 42.49 | 9.59 | 0.86% |
Sun Pharmaceutical Industries Ltd | 36.50 | 5.94 | 0.96% |
Cipla Ltd | 22.97 | 4.52 | 1.07% |
Dr Reddy's Laboratories Ltd | 19.39 | 3.88 | 0.61% |
JBCHEPHARM Stock Price Comparison
Compare JBCHEPHARM with any stock or ETFJBCHEPHARM Holdings
JBCHEPHARM Shareholdings
JBCHEPHARM Promoter Holdings Trend
JBCHEPHARM Promoter Holdings Trend
In last 6 months, promoter holding in the company has decreased by 5.90%
Pledged promoter holdings is insignificant
JBCHEPHARM Institutional Holdings Trend
JBCHEPHARM Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has increased by 3.66%
JBCHEPHARM Shareholding Pattern
JBCHEPHARM Shareholding Pattern
JBCHEPHARM Shareholding History
JBCHEPHARM Shareholding History
Mutual Funds Invested in JBCHEPHARM
Mutual Funds Invested in JBCHEPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding J B Chemicals and Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.5072% | Percentage of the fund’s portfolio invested in the stock 1.26% | Change in the portfolio weight of the stock over the last 3 months -0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/69 (-7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5071% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months -0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 103/139 (-12) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9043% | Percentage of the fund’s portfolio invested in the stock 1.79% | Change in the portfolio weight of the stock over the last 3 months -0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/103 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing JBCHEPHARM stock
smallcases containing JBCHEPHARM stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have J B Chemicals and Pharmaceuticals Ltd
JBCHEPHARM Events
JBCHEPHARM Events
JBCHEPHARM Dividend Trend
JBCHEPHARM has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.58 every year
Dividends
Corp. Actions
Announcements
Legal Orders
JBCHEPHARM Dividend Trend
JBCHEPHARM has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.58 every year
JBCHEPHARM Upcoming Dividends
JBCHEPHARM Upcoming Dividends
No upcoming dividends are available
JBCHEPHARM Past Dividends
JBCHEPHARM Past Dividends
Cash Dividend
Ex DateEx DateFeb 7, 2025
Dividend/Share
₹8.50
Ex DateEx Date
Feb 7, 2025
Cash Dividend
Ex DateEx DateAug 14, 2024
Dividend/Share
₹6.75
Ex DateEx Date
Aug 14, 2024
Cash Dividend
Ex DateEx DateFeb 16, 2024
Dividend/Share
₹5.50
Ex DateEx Date
Feb 16, 2024
Cash Dividend
Ex DateEx DateAug 17, 2023
Dividend/Share
₹9.25
Ex DateEx Date
Aug 17, 2023
Cash Dividend
Ex DateEx DateFeb 17, 2023
Dividend/Share
₹8.50
Ex DateEx Date
Feb 17, 2023
JBCHEPHARM Stock News & Opinions
JBCHEPHARM Stock News & Opinions
J B Chemicals & Pharmaceuticals has allotted 85,390 equity shares under ESOS. Consequently, the issued, subscribed and paid up capital has increased from 15,59,73,534 equity shares of Re. 1 each to 15,60,58,924 equity shares of Re. 1 each.Powered by Capital Market - Live
J B Chemicals & Pharmaceuticals has allotted 112,990 fully paid up equity shares of Re. 1/- each of the Company, to certain employees on exercise of stock options granted to them pursuant to JBCPL Employee Stock Option Scheme, 2021. An amount of Rs. 5,16,30,125 has been realised on exercise of 112,990 stock options. Consequently, the issued, subscribed and paid up capital has increased from 15,58,60,544 equity shares of Re. 1 each to 15,59,73,534 equity shares of Re. 1 each.Powered by Capital Market - Live
J B Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 700%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Net profit of J B Chemicals & Pharmaceuticals rose 15.48% to Rs 145.69 crore in the quarter ended March 2025 as against Rs 126.16 crore during the previous quarter ended March 2024. Sales rose 10.18% to Rs 949.48 crore in the quarter ended March 2025 as against Rs 861.73 crore during the previous quarter ended March 2024. For the full year,net profit rose 19.35% to Rs 659.58 crore in the year ended March 2025 as against Rs 552.63 crore during the previous year ended March 2024. Sales rose 12.45% to Rs 3917.99 crore in the year ended March 2025 as against Rs 3484.18 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales949.48861.73 10 3917.993484.18 12 OPM %23.8522.99 -26.3425.74 - PBDT239.47205.34 17 1058.43889.83 19 PBT193.03164.60 17 887.39751.51 18 NP145.69126.16 15 659.58552.63 19 Powered by Capital Market - Live
J B Chemicals & Pharmaceuticals has allotted 65,686 equity shares under ESOS on 05 May 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,56,77,208 equity shares of Re. 1 each to 15,57,42,894 equity shares of Re. 1 each.Powered by Capital Market - Live
J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live
The approved product is the generic version of Zebeta (marketed by Teva Pharmaceuticals) and is indicated for the management of hypertension. JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs, and intermediates. The company's consolidated net profit jumped 21.7% to Rs 162.49 crore on a 14.1% rise in net sales to Rs 963.49 crore in Q3 FY25 over Q3 FY24. Shares of JB Chemicals & Pharmaceuticals rose 0.47% to Rs 1,652.95 on the BSE.Powered by Capital Market - Live
J B Chemicals & Pharmaceuticals has received approval from United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Bisoprolol Tablets USP, 5 mg, and 10 mg, the generic version of Zebeta (Teva), which is indicated in the management of hypertension.Powered by Capital Market - Live
Capri Global Capital Ltd, RHI Magnesita India Ltd, Gujarat Pipavav Port Ltd, MMTC Ltd are among the other stocks to see a surge in volumes on NSE today, 27 March 2025.J B Chemicals & Pharmaceuticals Ltd witnessed volume of 110.79 lakh shares by 14:14 IST on NSE, a 96.3 times surge over two-week average daily volume of 1.15 lakh shares. The stock dropped 5.32% to Rs.1,617.85. Volumes stood at 75510 shares in the last session.Capri Global Capital Ltd witnessed volume of 1106.42 lakh shares by 14:14 IST on NSE, a 18.26 times surge over two-week average daily volume of 60.60 lakh shares. The stock dropped 13.43% to Rs.168.70. Volumes stood at 467.18 lakh shares in the last session.RHI Magnesita India Ltd witnessed volume of 154.53 lakh shares by 14:14 IST on NSE, a 12.41 times surge over two-week average daily volume of 12.46 lakh shares. The stock increased 10.18% to Rs.512.50. Volumes stood at 1.74 lakh shares in the last session.Gujarat Pipavav Port Ltd recorded volume of 129.28 lakh shares by 14:14 IST on NSE, a 7.05 times surge over two-week average daily volume of 18.32 lakh shares. The stock gained 5.79% to Rs.142.26. Volumes stood at 11.18 lakh shares in the last session.MMTC Ltd witnessed volume of 111.59 lakh shares by 14:14 IST on NSE, a 5.42 times surge over two-week average daily volume of 20.60 lakh shares. The stock increased 6.40% to Rs.55.85. Volumes stood at 29.33 lakh shares in the last session.Powered by Capital Market - Live
J B Chemicals & Pharmaceuticals has allotted 1,700 equity shares under ESOS on 18 March 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,56,75,508 equity shares of Re. 1 each to 15,56,77,208 equity shares of Re. 1 each.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.89%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.77% to 0.92%
Over the last 5 years, net income has grown at a yearly rate of 23.36%, vs industry avg of 15.29%